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Abstract
As numbers of coronavirus disease (COVID)-19 cases in the world rises gradually, both from unending first waves 
and resurging waves following successful reduction of cases on first waves, both the world and healthcare workers 
face an impending situation in the near future. For the world, the question may be, “When will we be allowed to 
work at our office again?” For caregivers, the question will be, “What may happen if over capacitance of healthcare 
facilities resumes until indeterminate time?” New published guidelines by WHO on clinical management of COVID-
19 provided most recent recommendations on criteria for stopping isolation of COVID-19 patients based on new 
findings that patients positive of severe acute respiratory syndrome coronavirus 2 is not always transmitting virus 
to surroundings. Furthermore, criteria for terminating isolation are suitable for all COVID-19 cases regardless of 
the location of isolation or the severity of the disease without the requirement of repeated swab examinations. 
This further gives an advantage by lowering healthcare costs and effective allocation of health resources. Even if a 
negative swab result is still a condition to be deemed not to be able to transmit the virus, this should not be a barrier 
for someone to return to their normal activity and lifestyle while waiting for the test swab results. In the end, the 
choice whether to pursue a result that has no clear benefits by allocating funds for repeated swab tests at expensive 
costs and ignoring the productivity of professionals by carrying out prolonged isolation or to optimize the resources 
at our disposal.
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Introduction
An important question often asked by a 
confirmed coronavirus disease (COVID)-19 patient is: 
“Doc, when will I be allowed to work at my office again?” 
followed by “Can I still transmit this virus to other people 
or my family?”
During these times – at least until this paper 
is written – patients recovered from COVID-19 may 
not simply be happy after getting past the acute 
phase of the disease. This is because at the next 
phase they will still need to wait for the next re-swab 
schedule, with the goal to find whether the person is 
still positive or is already negative of COVID-19, in 
other words, is the person still able to transmit the 
virus or not. During these waiting moments, they need 
to be isolated, unable to go to the office because of 
the stigma that the patient may still transmit the virus 
to other people, both at home and at the working 
environment, therefore, unable to contact closely 
and need to be physically distanced/stayed away 
from. Therefore, these long and rigorous processes 
may inflict a heavy psychological burden for a person 
recovered from COVID-19; and for patients without 
any symptoms, it may be something heavier than the 
disease itself. On the other side, there is no certainty 
in the matter of time that the following swab test will 
be negative. No matter how many times the test is 
conducted, there is no guarantee that the next one 
will be negative. WHO stated that the test may result 
in reactivity even though it was conducted weeks after 
the first infection, while CDC in August 2020 showed 
that a patient recovered from COVID-19 tested 3 
months after first infection may still be reactive to 
COVID-19 swab test [1].
The question is: If that is the reality and that a 
reactive swab test is identical to virus transmission, is a 
negative swab test result an absolute term for someone 
to live and move normally? Is there prove that someone 
with a reactive swab test result is still able to transmit 
severe acute respiratory syndrome coronavirus (SARS-
CoV)-2? [2].
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What is the Risk of Transmitting 
SARS-CoV-2?
COVID-19 is caused by an easily transmitted 
virus called SARS-CoV-2. After someone was exposed 
to this virus, the RNA virus will be able to be detected 
at the patient 1–3 days before the occurrence of any 
symptom. On the upper respiratory tract, viral load 
will reach its peak in the 1st week following exposure 
(highest on the 4th day after the symptoms occurred), 
followed by a progressive decrease over time. On 
feces and lower respiratory tract, viral load will reach its 
peak 2 weeks after first exposure. There is a tendency 
that the RNA virus will be detected longer on people 
with severe symptoms and immunodeficiency and 
that there is a connection between transmissibility and 
onset of symptoms. The highest risk for transmission 
occurs during symptoms onset and 5 days following the 
first infection. Usually, 5–10 days after SARS-CoV-2 
infection, patients infected will be producing neutralizing 
antibody progressively. The production of this antibody 
will lower the risk of infection. Based on these data, 10 
days following infection, the risk of patient transmitting 
COVID-19 is relatively low [3], [4].
Is SARS-CoV-2 Transmissible in a Reverse 
Transcriptase-polymerase Chain Reaction 
(RT-PCR) Positive Patients?
COVID-19 (SARS-CoV-2) is confirmed by 
the presence of the RNA virus detected through 
molecular tests, usually RT-PCR. The presence of 
RNA viruses in a person does not always mean that 
the person is infectious and can transmit the virus to 
other people [5], [6]. There are factors that determine 
the risk of transmission, namely the ability of the virus 
to replicate, symptoms such as coughing, infectious 
droplets, and environmental conditions and factors 
associated with the infected individual [4], [5].
In many viral diseases (e.g., SARS-CoV, 
MERS, influenza virus, Ebola virus, and Zika virus), 
it is well known that viral RNA can be detected for a 
long time after the infectious virus has ceased to exist. 
For example, measles virus, its viral RNA can still be 
detected 6–8 weeks after the infectious virus itself 
has disappeared. The immune system can neutralize 
the virus that prevents subsequent infections but does 
not eliminate nucleic acids, which remain detectable 
by RT-PCR, which will gradually decrease over 
time [5], [7], [8].
In COVID-19, the duration of infectious viral 
transmission period varies widely and may depend on 
the severity of the disease and the patient’s immune 
condition. A study obtained repeated viral RNA tests 
with negative results in 90% of cases with mild disease, 
while severe disease had positive results with a longer 
period of time [6], [9]. Zhou et al. reported that the median 
duration of the viral transmission period in COVID-19 
patients who were in severe or critical condition was 
31 days (range of 18–48 days) [7], [9], [10]. Wolfel 
et al. reported that COVID-19 patients with mild to 
moderate symptoms did not find the SARS-CoV-2 virus 
cultured from airway samples 8 days after of onset 
of symptoms. Other studies with varying degrees of 
disease have shown an inability to multiply the virus 
after days 7–9 of symptom onset [4],  [8], [11]. In a 
study of 129 critically ill COVID-19 patients, of whom 
30 were immunocompromised, the mean duration 
of viral transmission as measured by culture was 
8 days after onset, with the interquartile range of 
5–11 days [9], [12], [13]. The likelihood of detection of 
the virus on culture is <5% after 15.2 days of symptoms. 
This study as well as several other studies have 
reported a correlation between decreased infectivity 
with decreased viral load and increased neutralizing 
antibodies. Although viral RNA can be detected by 
RT-PCR even after symptoms have disappeared, the 
amount of viral RNA detected is substantially reduced 
over time and is generally below the threshold for the 
virus’ ability to replicate. Therefore, it is a safe approach 
to combine the time between the onset of symptoms 
and the disappearance of symptoms based on current 
data [4], [14].
When Can Patients Return to Work After 
Confirmed of COVID-19?
On 27 May 2020, WHO published guidelines on 
clinical management of COVID-19 and provided most 
recent recommendations on the criteria for stopping 
isolation of COVID-19 patients. The updates are based 
on new findings that asymptomatic patients still tested 
positive for the COVID-19 virus (SARS-CoV-2) with 
RT-PCR even for the following weeks. Even though 
the test result is still positive, it turns out that it cannot 
infect other people. The criteria for terminating isolation 
are suitable for all COVID-19 cases, regardless of 
the location of isolation or the severity of the disease 
and without requiring a repeat swab examination, 
namely: [4], [15], [16], [17]
1. For symptomatic patients: 10 days after 
symptom onset, plus at least 3 additional days 
without symptoms (including no fever and no 
respiratory symptoms)
2. For asymptomatic cases: 10 days after testing 
positive for SARS-CoV-2.
This latest WHO recommendation 
(27 May) differs from and also revises the previous 
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recommendation (12 January) that patient isolation 
is terminated upon clinical recovery and two negative 
RT-PCR results are obtained in sequential samples 
taken at least 24 h apart [10].
Based on the CDC, there are three principles to 
stop isolation of COVID-19 patients, namely “symptom-
based strategies,” “time-based strategies,” and “test-
based strategies.” The “symptom-based strategy” 
is the CDC’s latest revised release for isolation for 
symptomatic COVID-19 patients. Patients may move 
out from isolation and return to work if the following 
three conditions are met [10], [17], [18]:
1. At least 10 days from when symptoms first 
appeared; and
2. At least 24 h since the last fever without using 
fever-reducing drugs; and
3. All COVID-related symptoms (e.g., cough and 
shortness of breath) have improved.
The “time-based strategy” remains valid for 
patients with a positive but asymptomatic swab test 
(i.e., 10 days of isolation from the date of positive 
test), as well as for patients (including healthcare 
professionals) with severe to critical illness or who are 
severely immunocompromised. Adults, the duration is 
at least 10 days–20 days after symptom onset, while the 
“test-based strategy” is no longer resisted by the CDC 
(except in severely immunocompromised patients). The 
reason it is no longer considering a test-based strategy 
is that it will result in prolonged isolation because the 
SARS-CoV-2 RNA virus is still detected, but the patient 
is not able to transmit the virus anymore (CDC, update 
August 10) [11], [19].
In our hospital (a University Hospital in Bali, 
Indonesia), when our government adopts the old 
criteria from WHO, we used 2 times negative results 
of PCR for stopping isolation, many problems happen. 
In many cases, sometimes patients already did not 
have any symptoms again, but the PCR result is still 
positive. In our hospital from April until June 2020, 42 
(16.5%) patients have hospitalized for more than 14 
days, even though they do not have any symptom, 
but the PCR results were positive. One of the patient, 
already hospitalized 58 days, but she did not have any 
symptom since day 6 after admission. Since July 2020, 
our government adopts the newest WHO guidelines. 
From that time, the length of patient care can be shorter. 
The average patient was treated for 13–14 days.
Public Health Impact
This study focuses on the exploration of 
COVID-19 patients isolation time and factors in 
relation to isolation time. We also did a literature-based 
critical analysis on the exact necessity of prolonged 
isolation time as well as repeated swab test in deciding 
whether a COVID-19 patient is to be released from 
hospitalization or not. Based on the finding of this 
study, we could conclude that approximately 2-weeks 
isolation time starting from symptoms onset is safe 
and reliable enough as a standard for COVID-19 
patient release, especially those with mild symptoms. 
Thus, the result of this study poses as scientific-based 
supporting data to aid effective decision making for 
stakeholders in the management of health resources 
regarding COVID-19 inpatients and hospitalization, 
namely, a faster release of COVID-19 patients after 14 
days of hospitalization means there will be more space 
of new patients, specifically those critically ill and in 
need of active supervision. Other than hospital bed and 
facilities, fewer patients to tend also means healthcare 
team could also put more focus on urgent and severe 
patients, increasing productivity and lessening burden, 
which might lead to medical errors. The results from 
this study could also be considered by the government 
and local ministry of health to reconsider and perhaps 
change their old way of managing COVID-19 funds. The 
previous statement refers to the fact that “unnecessary” 
fund spent on hospital fee for mild or recovered patients 
with no symptoms who are fully capable of home-care 
and self-quarantine is a waste of resources, which 
could be allocated more effectively for other aspects of 
COVID-19 management [19], [20].
Perspective
Based on research evidence and 
recommendations from WHO and CDC above, of 
course, it will raise a belief that the negative swab 
criteria as a reference for someone to be able to stop 
their isolation and be allowed to return to work are 
no longer relevant to be applied because there is no 
rational basis for using the negative swab reference to 
be considered cured of COVID-19.
Sometimes professionals who are accustomed 
to critical thinking who always put forward evidence 
(evidenced based) forget about this. It may be that this 
is based on excessive worry and fear of contracting 
so that in the end, they put forward baseless opinions 
and no longer consider the aftereffects as a result of 
improper application of guidelines.
In this world, no one is the same, everyone has 
their own uniqueness. Likewise, there is no diagnosis of 
the same disease, which will give the same outcome. 
It is commonly known in medical circles that the 
management of disease must apply the principles of 
personalized medicine and an individualized treatment 
approach. Implementing an action must be personal 
or individual and in accordance with the conditions at 
that time. This also applies for patients with confirmed 
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COVID-19. Before deciding on the next step (e.g., the 
length of time for isolation and the need for a re-swab 
for evaluation), an evaluation of each condition must 
be carried out individually, especially the presence 
or absence of symptoms (mild, moderate, severe, or 
critical), the presence or absence of sequelae that may 
describe the severity of the complications that occur, 
the presence or absence of comorbid conditions, and 
so on. This is so that the available resources, which are 
generally limited, will actually be used effectively and 
efficiently and can be allocated to other needs that are 
more appropriate. From patient’s perspective, there is a 
sense of satisfaction after having received proper care, 
which has been adjusted to their personal conditions.
Even if a negative swab is still a condition need 
to be met to be deemed not to transmit the virus, then this 
should not be a barrier for someone to be able to return 
to their normal activity and lifestyle while waiting for the 
test swab results. The person (the “patient”) is clear, has 
been confirmed with COVID-19, so with this clear status, 
it is easier to be able to implement stricter transmission 
prevention patterns, for example, using N95 masks or the 
equivalent, especially when treating patients for health 
workers. The application of a more stringent pattern of 
prevention of transmission over a certain period of time 
in patients with confirmed COVID-19 feels more human 
while waiting for a laboratory examination schedule 
(if necessary) rather than isolation.
Another thing that needs to be paid attention 
to regarding the mere provision of the negative swab 
is the risk of a shortage of staff/professionals to care 
for patients, especially if there is a significant spike in 
confirmed positive COVID-19 cases affecting medical 
professionals. At the same time, to anticipate this, 
health facilities must be prepared to face potential staff 
shortages and have a plan and process to address 
them, including by implementing the latest WHO and 
CDC recommendations.
WHO does not prohibit a country from 
continuing to use the recommendation issued at the 
beginning of the pandemic, namely 2 negative swabs 
with a distance of at least 24 h as a criterion for 
stopping isolation. On the other hand, we all certainly 
agree that the facilities and infrastructure that we 
have related to COVID-19 are still very limited, still 
far from the minimum required. Therefore, the use of 
sophisticated and expensive laboratories such as the 
RT-PCR examination for SAR-CoV-2 virus must be 
right on target, allocated appropriately, so that it can 
reach more target patients. How much money can be 
saved if the RT-PCR examination is only done once 
for each patient for diagnostic purposes only, without 
re-examinations that may need to be repeated many 
times with a target of only negative swab results? A 
laboratory-based approach may still have a place for 
COVID-19 patients, but of course, it is selective, only in 
patients with certain conditions based on the evaluation 
of a competent doctor.
In the end, the choice is ours, whether to 
pursue something that has no clear benefits (keep 
allocating funds for swab tests at this inexpensive cost 
and ignore the productivity of professionals by carrying 
out prolonged isolation), or whether we will optimize 
the resources we have at our disposal. Our country, 
Indonesia, is a country that belongs to the developing 
country category with limited resources, so if there is a 
good choice and at a much cheaper cost, of course, we 
will choose it.
Conclusion
Based on the evidence that shows that the 
virus can no longer be cultured (no ability to replicate) 
after 9 days from the onset of symptoms (especially in 
patients with mild disease), it is safe to stop isolating 
COVID-19 patients based on clinical criteria with a 
minimum isolation time of 13 days since symptom 
onset, and not strictly based on repeated PCR results. 
Whereas in patients with severe or critical symptoms, 
as well as those with severe immune disorders, a 
laboratory-based approach (measurement of viral load 
and neutralizing antibodies) may be helpful in making 
decisions about whether or not a person should undergo 
prolonged isolation [12].
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